A Phase 2 interventional study of NT-501 CNTF implant in Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Telangiectasis with a site in United States — 5 open to participants now, 5 under way, 2 of them phase 3. Telangiectasis · United States.
Among the 33 studies in Telangiectasis with a site in United States, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 27th registered.
69 studies on the registry are indexed under Telangiectasis; 12 are open to participants now.
Browse Telangiectasis studies →5 of the 33 studies in Telangiectasis with a site in United States are open now. Recruiting first, the newest first:
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 18+
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 21–80
Cure HHT · Sites in United States
Healthy volunteers
The Lowy Medical Research Institute Limited · Sites in United States, Australia, Germany and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Telangiectasis studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is close to the median of 30 across 59 interventional studies indexed under Telangiectasis.
Median enrollment 20 across the 31 interventional studies, 5,011 across the 2 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Neurotech Pharmaceuticals has 7 studies filed under Telangiectasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Telangiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
This was a multicenter, open-label study designed to evaluate the safety of bilateral NT-501 in subjects with MacTel. All subjects who received NT-501 in a single eye prior to or in the Phase 1/2 extension study (NTMT-01/02E) or in 1 of the 2 Phase 3 studies (NTMT-03-A or NTMT-03-B), and met all other eligibility criteria, qualified for participation in the current study; enrolled subjects underwent intraocular implantation of NT-501 in the fellow eye and were followed for 6 months. Note that, throughout this report, all references to "study eye" mean the eye that received NT-501 in the current study (ie, not the eye that was treated in the previous study).
General Inclusion Criteria
Ocular Inclusion Criteria
General Exclusion Criteria
Females of childbearing potential (those who are not surgically sterilized or post- menopausal, i.e., absence of menstruation for 12 months or longer) may not participate in the study if any of the following conditions exists:
Ocular Exclusion Criteria
Participant has a history or evidence of the following surgeries/procedures in the study eye, as assessed at Visit 1, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NT-501 was implanted on Day 0 in the fellow eye of subjects who received a single NT-501 in a previous study; subjects were followed for 6 months post-implantation of NT-501 in this study.
Combination Product: NT-501 CNTF implant
Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events
Assess the incidence and severity of adverse events (AEs) following bilateral ocular implantation of NT-501
Time frame: 6 months
Serum Levels of CNTF and Immunogenicity for NT-501
Incidence of positive serum levels of CNTF and immunogenicity for NT-501 with quantification of antibodies (Ab) to CNTF, neutralizing antibodies (NAb) to CNTF, Ab to NTC-201-6A cells, and Ab to mouse dihydrofolate reductase (mDHFR) at any time.
Time frame: 6 months
Of the 33 enrolled subjects, 32 (97.0%) received NT-501; the exception was a subject whose surgery was canceled due to an event of arterial fibrillation that occurred prior to surgery and resulted in subject discontinuation. No subject had NT-501 removed from either eye during the study, and all 32 subjects who received NT-501 in this study completed the study.
| Milestone | NT-501 in Fellow Eye |
|---|---|
| Started | 33 |
| Nt-501 implanted in study eye | 32 |
| Completed | 32 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Assess the incidence and severity of adverse events (AEs) following bilateral ocular implantation of NT-501
| Participants | NT-501 in Fellow Eye |
|---|---|
| At least 1 TEAE | 26 |
| At least 1 ocular TEAE in study eye | 26 |
| At least 1 ocular TEAE in fellow eye | 6 |
| At least 1 nonocular TEAE | 13 |
| At least 1 treatment related ocular TEAE | 26 |
| At least 1 treatment related nonocular TEAE | 0 |
| At least 1 SAE | 2 |
| NT-501 removal from either eye | 0 |
Incidence of positive serum levels of CNTF and immunogenicity for NT-501 with quantification of antibodies (Ab) to CNTF, neutralizing antibodies (NAb) to CNTF, Ab to NTC-201-6A cells, and Ab to mouse dihydrofolate reductase (mDHFR) at any time.
| Participants | NT-501 in Fellow Eye |
|---|---|
| CNTF Positive | 0 |
| Ab Positive to CNTF | 1 |
| Neutralizing Ab to CNTF | 0 |
| Ab to NTC | 0 |
| ab to DHRF | 0 |
Collected over Through 6 months post implant. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NT-501 in Fellow Eye | 0/32 (0%) | 2/32 (6.3%) | 26/32 (81.3%) |
| Event | NT-501 in Fellow Eye |
|---|---|
| Device ExtrusionSurgical and medical procedures | 1/32 |
| Feces discoloredGastrointestinal disorders | 1/32 |
| Event | NT-501 in Fellow Eye |
|---|---|
| Eye painEye disorders | 9/32 |
| Ocular discomfortEye disorders | 9/32 |
| Conjunctival haemorrhageEye disorders | 8/32 |
| Eye irritationEye disorders | 4/32 |
| Dry eyeEye disorders | 2/32 |
| Anterior chamber cellEye disorders | 1/32 |
| Anterior chamber flareEye disorders | 1/32 |
| CataractEye disorders | 1/32 |
| Cataract subcapsularEye disorders | 1/32 |
| Conjunctival hyperaemiaEye disorders | 1/32 |
Baseline demographics and characteristics are based on total number of participants who completed NT-501 implant in study eye
| Age, Customized(years) | NT-501 in Fellow Eye |
|---|---|
| Age (Years) | 63.0 ± 6.55 |
| Age, Customized(Participants) | NT-501 in Fellow Eye |
|---|---|
| 50 to < 60 years | 9 |
| 60 to < 70 years | 17 |
| > or = to 70 years | 6 |
| Sex: Female, Male(Participants) | NT-501 in Fellow Eye |
|---|---|
| Female | 24 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | NT-501 in Fellow Eye |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 30 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | NT-501 in Fellow Eye |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| BCVA (letters) for Study Eye(letters correctly read) | NT-501 in Fellow Eye |
|---|---|
| Study Eye | 68.7 ± 11.01 |
| Fellow Eye | 70.1 ± 9.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Dec 2022, 16 months.
Results were first posted in Mar 2025, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciliary Neurotrophic Factor
Neurotech Pharmaceuticals